Gastroparesis
Drug research and approvals for gastroparesis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 44 studies of gastroparesis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 44
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
- Gastric Focused Ultrasound StimulationNCT07851727 · Not applicable · Evan (Huiliang) Wang · starts Sep 11, 2026
- Gastric Emptying and Enteral Nutrition Tolerance According to Vasopressor Dose in ICU PatientsNCT07802379 · Not reported · Başakşehir Çam & Sakura City Hospital · starts Sep 1, 2026
- Evaluating Whether a Nausea Band Reduces Symptoms in Those With Chronic Nausea VomitingNCT07720323 · Not applicable · Ohio State University · starts Feb 1, 2023
- Virtual Poetry Workshops to Enhance Patient Well Being and Reduce AnxietyNCT07717541 · Not applicable · Ohio State University · starts Jul 17, 2026
- Effect of Virtual Yoga in Diabetic Gastroparesis PatientsNCT07717554 · Not applicable · Ohio State University · starts Jul 17, 2026
- The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After PancreaticoduodenectomyNCT07681128 · Not applicable · Tianjin Medical University Cancer Institute and Hospital · starts Mar 30, 2026
- Effect of Gastric Electrical Stimulation on Serum Insulin LevelsNCT07635576 · Not applicable · Indiana University · starts Jul 23, 2026
- Acupuncture for Postoperative Gastric Emptying DelayNCT07505927 · Not applicable · Qilu Hospital of Shandong University · starts Apr 1, 2026
- Delayed Gastric Emptying After Pancreatic SurgeryNCT07382791 · Not reported · National Taiwan University Hospital · starts Jan 1, 2016
Approved 1
- MetoclopramideDopamine D2 receptor antagonist
Phase 3 4
- DomperidoneDopamine D2 receptor antagonist
- TradipitantNeurokinin 1 receptor antagonist
- NortriptylineSerotonin transporter inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Phase 2 12 of 24
- CamicinalMotilin receptor agonist
- Dextrose
- ErythromycinBacterial 70S ribosome inhibitor
- VelusetragSerotonin 4 (5-HT4) receptor agonist
- UlimorelinGhrelin receptor agonist
- PromethazineHistamine H1 receptor antagonist
- TadalafilPhosphodiesterase 5A inhibitor
- OndansetronSerotonin 3a (5-HT3a) receptor antagonist
- GranisetronSerotonin 3a (5-HT3a) receptor antagonist
- BuspironeSerotonin 1a (5-HT1a) receptor partial agonist
- MethylnaltrexoneMu opioid receptor antagonist
- NeostigmineAcetylcholinesterase inhibitor
Phase 1 or earlier 7
- KetoconazoleCytochrome P450 51 inhibitor
- LisinoprilAngiotensin-converting enzyme inhibitor
- NizatidineHistamine H2 receptor antagonist
- SimpiniclineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- ItoprideDopamine D2 receptor antagonist
- OxytocinOxytocin receptor agonist
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
How its trials ended
291 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 87 whose ending is known, 28% met their primary endpoint, 6% missed it and 67% stopped early.
- Ongoing9332%
- Completed, result not reported8429%
- Stopped: other or unclear3612%
- Status unknown279%
- Met its primary endpoint248%
- Stopped: enrollment or feasibility114%
- Stopped: sponsor or business decision93%
- Missed its primary endpoint52%
- Stopped: lack of efficacy21%
| Oct 21, 2024 | Primers - a phase II, prospective, randomized, double-blinded, parallel group, placebo-controlled investigation of metoclopramide effects on full-stomach rates…Metoclopramide | Thunder Bay Regional Health Research Institute | Pending |
| Jul 24, 2019 | Open-label extension study of relamorelin for the treatment of diabetic gastroparesisRelamorelin | AbbVie | Closed |
| Jun 4, 2018 | A 52-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic…Relamorelin | AbbVie | Closed |
| May 14, 2018 | A 46-week, double-blind, placebo-controlled, phase 3 study with a 6-week randomized-withdrawal period to evaluate the safety and efficacy of relamorelin in…Relamorelin | AbbVie | Closed |
| Dec 15, 2017 | A 12-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic…Relamorelin | AbbVie | Closed |
| Dec 4, 2013 | Prucalopride versus placebo in diabetic gastroparesis: randomized placebo-controlled crossover trialPrucalopride | University of Calgary | Closed |
| Sep 11, 2013 | Nutritional adequacy therapeutic enhancement in the critically ill: a randomized double blind, placebo-controlled trial of the motilin receptor agonist…GSK962040 | GSK | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA